Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 123,950,736
  • Shares Outstanding, K 2,529,607
  • Annual Sales, $ 50,266 M
  • Annual Income, $ 5,844 M
  • 60-Month Beta 0.61
  • Price/Sales 2.73
  • Price/Cash Flow 7.57
  • Price/Book 1.52
Trade SNY with:

Options Overview Details

View History
  • Implied Volatility 20.37% ( -3.69%)
  • Historical Volatility 27.64%
  • IV Percentile 28%
  • IV Rank 17.60%
  • IV High 39.81% on 04/24/24
  • IV Low 16.21% on 08/23/23
  • Put/Call Vol Ratio 1.74
  • Today's Volume 285
  • Volume Avg (30-Day) 2,809
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 34,678
  • Open Int (30-Day) 41,775

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.87
  • Number of Estimates 4
  • High Estimate 0.90
  • Low Estimate 0.85
  • Prior Year 0.95
  • Growth Rate Est. (year over year) -8.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.10 +0.91%
on 05/09/24
50.59 -4.05%
on 05/22/24
+1.93 (+4.14%)
since 04/24/24
3-Month
45.22 +7.34%
on 04/18/24
50.59 -4.05%
on 05/22/24
-0.23 (-0.47%)
since 02/23/24
52-Week
42.63 +13.86%
on 10/27/23
55.72 -12.89%
on 09/20/23
-5.43 (-10.06%)
since 05/24/23

Most Recent Stories

More News
Why Vaccine Stocks Rallied This Week

A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?

SNY : 48.54 (-0.94%)
MRNA : 166.61 (+1.59%)
NVAX : 15.50 (+2.31%)
BNTX : 96.95 (-2.07%)
PFE : 28.88 (+0.66%)
3 Things You Need to Know If You Buy Novavax Today

The vaccine maker's recovery story is looking brighter.

SNY : 48.54 (-0.94%)
PFE : 28.88 (+0.66%)
NVAX : 15.50 (+2.31%)
This Stock Just More Than Doubled in 1 Day: Is It a Buy?

The biotech still hasn't lost momentum.

NVAX : 15.50 (+2.31%)
SNY : 48.54 (-0.94%)
Could Novavax Become the Next Moderna?

Sanofi believes in Novavax's vaccine strengths...

SNY : 48.54 (-0.94%)
PFE : 28.88 (+0.66%)
NVAX : 15.50 (+2.31%)
MRNA : 166.61 (+1.59%)
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now

These two healthcare stocks may be deeply undervalued.

ETN : 340.89 (+0.73%)
CPRX : 15.87 (-0.31%)
NVAX : 15.50 (+2.31%)
SNY : 48.54 (-0.94%)
Novavax Stock Just Tripled. Is It Too Late to Buy?

Novavax shares have soared and plummeted in recent years.

SNY : 48.54 (-0.94%)
NVAX : 15.50 (+2.31%)
Does Soaring Novavax Stock Have Enough Fuel to Climb Higher?

Moderate success regarding a new licensing deal with Sanofi could make the troubled vaccine stock a top performer.

PFE : 28.88 (+0.66%)
NVAX : 15.50 (+2.31%)
SNY : 48.54 (-0.94%)
Why Novavax Stock More Than Doubled Today

A cloud of doubt hanging over the company just gave way to some sunshine.

NVAX : 15.50 (+2.31%)
SNY : 48.54 (-0.94%)
Sanofi's New Cancer Drug Could Help Deliver a Big Payday

Investors should expect a modest 2024 before seeing more exciting returns for the drugmaker in 2025 following the expected approval of rilzabrutinib.

SNY : 48.54 (-0.94%)
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond

It pays to develop novel medicines for life-threatening illnesses.

CRSP : 55.24 (-0.88%)
REGN : 985.02 (+0.45%)
SNY : 48.54 (-0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 49.19
2nd Resistance Point 49.02
1st Resistance Point 48.78
Last Price 48.54
1st Support Level 48.37
2nd Support Level 48.20
3rd Support Level 47.96

See More

52-Week High 55.72
Fibonacci 61.8% 50.72
Fibonacci 50% 49.18
Last Price 48.54
Fibonacci 38.2% 47.63
52-Week Low 42.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar